» Articles » PMID: 29464785

Astrocytes Sustain Long-term Productive HIV-1 Infection Without Establishment of Reactivable Viral Latency

Overview
Journal Glia
Specialty Neurology
Date 2018 Feb 22
PMID 29464785
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

The "shock and kill" HIV-1 cure strategy proposes eradication of stable cellular reservoirs by clinical treatment with latency-reversing agents (LRAs). Although resting CD4 T cells latently infected with HIV-1 constitute the main reservoir that is targeted by these approaches, their consequences on other reservoirs such as the central nervous system are still unknown and should be taken into consideration. We performed experiments aimed at defining the possible role of astrocytes in HIV-1 persistence in the brain and the effect of LRA treatments on this viral sanctuary. We first demonstrate that the diminished HIV-1 production in a proliferating astrocyte culture is due to a reduced proliferative capacity of virus-infected cells compared with uninfected astrocytes. In contrast, infection of non-proliferating astrocytes led to a robust HIV-1 infection that was sustained for over 60 days. To identify astrocytes latently infected with HIV-1, we designed a new dual-color reporter virus called NL4.3 eGFP-IRES-Crimson that is fully infectious and encodes for all viral proteins. Although we detected a small fraction of astrocytes carrying silent HIV-1 proviruses, we did not observe any reactivation using various LRAs and even strong inducers such as tumor necrosis factor, thus suggesting that these proviruses were either not transcriptionally competent or in a state of deep latency. Our findings imply that astrocytes might not constitute a latent reservoir per se but that relentless virus production by this brain cell population could contribute to the neurological disorders seen in HIV-1-infected persons subjected to combination antiretroviral therapy.

Citing Articles

Virus-Shaped Mesoporous Silica Nanostars to Improve the Transport of Drugs across the Blood-Brain Barrier.

Pinna A, Ragaisyte I, Morton W, Angioletti-Uberti S, Proust A, DAntuono R ACS Appl Mater Interfaces. 2024; 16(29):37623-37640.

PMID: 38988046 PMC: 11284754. DOI: 10.1021/acsami.4c06726.


A Canadian Survey of Research on HIV-1 Latency-Where Are We Now and Where Are We Heading?.

Abdalla A, Guajardo-Contreras G, Mouland A Viruses. 2024; 16(2).

PMID: 38400005 PMC: 10891605. DOI: 10.3390/v16020229.


Neurological, Behavioral, and Pathophysiological Characterization of the Co-Occurrence of Substance Use and HIV: A Narrative Review.

Vines L, Sotelo D, Giddens N, Manza P, Volkow N, Wang G Brain Sci. 2023; 13(10).

PMID: 37891847 PMC: 10605099. DOI: 10.3390/brainsci13101480.


HIV Latency and Nanomedicine Strategies for Anti-HIV Treatment and Eradication.

Andre M, Nair M, Raymond A Biomedicines. 2023; 11(2).

PMID: 36831153 PMC: 9953021. DOI: 10.3390/biomedicines11020617.


HIV infection of non-classical cells in the brain.

Wahl A, Al-Harthi L Retrovirology. 2023; 20(1):1.

PMID: 36639783 PMC: 9840342. DOI: 10.1186/s12977-023-00616-9.